[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biovie Inc (BIVI)

Biovie Inc (BIVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,825
  • Shares Outstanding, K 7,543
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,070 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.03
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.15
  • Most Recent Earnings $-0.70 on 08/12/26
  • Next Earnings Date 11/09/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8200 +17.61%
on 08/06/26
3.7900 -74.55%
on 08/12/26
-0.8356 (-46.42%)
since 07/17/26
3-Month
0.8200 +17.61%
on 08/06/26
3.7900 -74.55%
on 08/12/26
-0.3956 (-29.09%)
since 05/18/26
52-Week
0.8200 +17.61%
on 08/06/26
3.7900 -74.55%
on 08/12/26
-0.7856 (-44.89%)
since 08/18/25

Most Recent Stories

More News
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

ORLANDO, FL / ACCESS Newswire / August 14, 2026 / RedChip Companies will air interviews with First Phosphate Corp. (NASDAQ:PHOS)(CSE:PHOS)(OTCQX:FRSPF)(FSE:KD0) and BioVie Inc. (Nasdaq:BIVI) on the RedChip...

PHOS.CN : 2.3000 (-5.74%)
BIVI : 0.9644 (-17.57%)
PHOS : 16.49 (-6.89%)
FRSPF : 1.6500 (-5.71%)
New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results

Sponsored Programming Also Broadcasts Across Bloomberg Television in Latin America and MENA, Expanding the Global Reach of New to The Street's Featured Companies

CAST : 2.1000 (+144.24%)
RHNO : 8.0000 (+10.34%)
IGC : 0.2844 (+1.57%)
BIVI : 0.9644 (-17.57%)
VTIX : 1.5900 (-5.92%)
LTRN : 2.52 (-3.08%)
BSIN : 1.3900 (-2.11%)
DVLT : 0.3867 (+20.73%)
COCH : 0.7389 (+0.53%)
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results

BioVie CEO Cuong Do to discuss the newly released Phase 2 SUNRISE-PD results and what they mean for the future development of bezisterim in Parkinson's disease

BIVI : 0.9644 (-17.57%)
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease

Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS 1 Parts I, II, and III, as well...

BIVI : 0.9644 (-17.57%)
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

BIVI : 0.9644 (-17.57%)
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / May 29, 2026 / RedChip Companies will air interviews with Foremost Clean Energy Ltd. (Nasdaq:FMST)(CSE:FAT) and BioVie, Inc. (Nasdaq:BIVI) on the RedChip Small Stocks, Big...

BIVI : 0.9644 (-17.57%)
FMST : 1.1400 (-4.20%)
FAT.CN : 1.5500 (-7.74%)
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 0.9644 (-17.57%)
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

-Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing...

BIVI : 0.9644 (-17.57%)
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease

CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 0.9644 (-17.57%)
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 0.9644 (-17.57%)

Business Summary

BioVie Inc. engages in developing drug therapies for liver disease. The company's product candidate includes BIV201, which are in clinical stage. BioVie Inc. is based in SANTA MONICA, CA.

See More

Key Turning Points

3rd Resistance Point 1.2829
2nd Resistance Point 1.2115
1st Resistance Point 1.0879
Last Price 0.9644
1st Support Level 0.8929
2nd Support Level 0.8215
3rd Support Level 0.6979

See More

52-Week High 3.7900
Fibonacci 61.8% 2.6555
Fibonacci 50% 2.3050
Fibonacci 38.2% 1.9545
Last Price 0.9644
52-Week Low 0.8200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.